All posts by medical

Meet the women who are turning to sperm donation to become solo mums – The Sun

AFTER a challenging 17-hour labour, Laura Holloway held her newborn daughter in her arms.

With her mum Kath, 60, by her side, she gazed at Violet and knew shed done the right thing by having a baby on her own.

11

Id never been more sure of anything, says Laura, 32, from Derby. I had no room for a man in my life at that time.

"People say: Youre so brave. But I would have been braver if Id left having a baby to fate. I was getting the one thing I really wanted, rather than risking waiting longer.

Laura is not alone. A recent report from the Human Fertilisation and Embryology Authority (HFEA) revealed that more women than ever are seeking sperm donation to become a solo mum.

It reported a four per cent increase in single women undergoing IVF cycles between 2016 and 2017, and a six per cent rise in single women undergoing intrauterine insemination (IUI), in which sperm is inserted into the womb.

In October this year, actress and singer Natalie Imbruglia announced she had given birth to son Max Valentine after using a sperm donor.

Meanwhile, last April, former X Factor judge Cheryl told a newspaper she didnt think you needed to be in a relationship to have children. There are definitely other routes I would consider, she said.

11

Theres been a big shift in womens roles: we have been encouraged to have jobs and take up opportunities that our mothers and grandmothers never had, says Caroline Spencer, fertility coach at the Lister Fertility Clinic.

But at the same time its also expected that we would have a relationship and for many women thats not happened. Some turn to egg freezing, while others opt to go it alone.

Of course, there are no guarantees. According to the HFEA, birth rates for IVF decline as women age, from 25 per cent for those under 35, to 16 per cent if aged 35-37 and 14 per cent for those aged 38-39, to eight per cent for those aged 40-42.

For IUI, the percentages are even lower 19 per cent for under 35s, 14 per cent for those aged 35-39 and 5 per cent for those aged 40-42.

Its expected that we would have a relationship and for many women thats not happened. Some turn to egg freezing, while others opt to go it alone.

The odds arent great, but women like Laura are ready to take the chance. Having a baby was always important to me, she explains.

Then in my late 20s I was told I might have endometriosis, so I needed to get on with it. However, the men I dated werent right. There wouldnt be any connection but Id push it, thinking I needed to give it another try.

11

"I realised I was so desperate to have children, I was looking for a guy who could father a child, rather than looking for love. So I decided to do it myself.

The first person Laura spoke to was her mum, who went with her to appointments at Care Fertility in Nottingham.

Then, in January 2018, Laura paid the clinic 3,280 using money she had inherited following the death of her father Phil in 2005 which covered tests, consultations, sperm and the drugs needed.

It felt like the perfect thing to spend it on. Mum encouraged me to do it, says Laura. I thought shed say I needed to get married, but she was excited.

Because of her age, Laura was offered the less intrusive IUI. I met with a donor nurse at the clinic and she went through a series of questions relating to what I wanted in a sperm donor, such as hair colour, eye colour and height, she explains.

I thought it was ridiculous, because I wouldnt chose whether to date a man based on the colour of his eyes! The only criteria I had was that he was Caucasian, like me.

11

Twelve days after insertion, a home test revealed Laura was pregnant and she was overjoyed.

Despite a difficult pregnancy during which she wrestled with nausea that meant she had to have time off work, she was certain she had done the right thing, and her daughter Violet was born on March 27, 2019.

I remember clinging on to Mum during the birth, Laura says. She had my sick all over her, but she understood. Shed done it herself, whereas a man wouldnt have known what I was going through.

From the minute I held Violet, Ive never looked back for a second. When I am ready to date again, Ill go into it so much more relaxed, because Ive got what I wanted I have my baby. So this time around, hopefully Ill meet someone for the right reasons.

Caroline explains its important that women thinking about solo parenthood carefully consider how much help theyll need, both during the pregnancy and after the baby is born.

From the minute I held Violet, Ive never looked back for a second. When I am ready to date again, Ill go into it so much more relaxed.

We encourage women to think about the support networks theyll need, to think very carefully about who would be the person you could phone to get more Calpol in the night or who will be there for you when you feel totally overwhelmed, she says.

11

Camilla Pratt, 35, from Leeds, knows only too well how difficult it can be. A lecturer in primary education, Camilla eventually decided to embark on fertility treatment in January 2018.

I always knew I was going to be a solo mum. Relationships hadnt worked out for me, and I was never interested enough in anyone, she says.

So I went to a Donor Conception Network conference, researched on Google and went on to have IVF costing around 2,800 in January 2018. I conceived on my second try.

With extreme sickness and tiredness, Camilla struggled both physically and emotionally during her pregnancy.

Women need to think about how much help they'll need, both during the pregnancy and after the baby is born.

I couldnt do all the things I used to do, like play lacrosse, plus work was tough, she says. Friends helped as much as they could, but it was a horrible and extremely gruelling time. It was the same during the birth.

"Two friends were my birthing partners, but I felt so sick and dehydrated, and then Oscar got stuck in the birth canal. After 36 hours, I had an episiotomy and emergency forceps delivery. I was in hospital for five days.

11

In the weeks after the birth in January 2019, Camillas family and friends rallied round when she didnt even have the strength to get out of bed. Her parents came to stay, followed by a friend, while another friend organised a night nanny.

That April she needed two further operations to help repair the damage shed suffered during labour, and after her surgery, her parents took her and Oscar to stay with them for three weeks.

I felt like Id never even make it to the supermarket again, like Id never have a whole night of sleep or leave the house, she remembers.

I was thinking: What have I done? I had a lovely life! I knew it would be challenging, but I didnt realise how much time I would need to recover physically, as well as deal with a baby in my arms.

After three and a half months I began to feel like I could be a mum, and to enjoy it without being in pain or so tired.

"Now, 11 months in, Im back at work full-time and making sure I get out in the evenings two or three times a week to do sport my friends babysit or I take my son with me to a mother and baby class, and Im feeling so much more positive.

11

Camillas not currently dating, but she hasnt ruled it out in the future. She has also frozen some embryos should she decide to go it alone a second time.

It would be nice for Oscar to have a sibling, especially as hes donor-conceived it would give them a unique bond, she says.

As well as the practical difficulties, some solo mums also struggle emotionally particularly with letting go of the dream of having a baby with a man they love.

The vast majority of the women that Ive coached are nervous, says Mel Johnson, founder of The Stork And I, a support and coaching service for women considering solo motherhood.

There are three main things that cause anxiety: grieving the loss of having a baby in a relationship, whether theyll physically, practically and emotionally be able to cope, and managing loneliness. Its all about letting go of the fairy tale that you grew up with.

Susie*, a digital communications manager from Surrey, was particularly affected by this sense of grief.

11

It did take me a while to accept that using a sperm donor was going to be both mine and my childs story, forever, says Susie, 45, whose daughter Katie* is now eight.

There were days when Id walk round the park crying, wondering what Id done. Theres a relentlessness to parenting on your own and the solo mums path is hard to travel.

Susie says she thinks theres no longer a huge stigma in admitting youve had solo IVF but admitting to regrets is a different matter.

I think there are plenty of solo mums who have regrets, myself included, but for many, admitting it is possibly more of a taboo than saying theyve had solo IVF, she says. Its not that I wish I hadnt done it at all, its more that I wish I hadnt had to.

I still feel sad Ill never know what its like to share the experience of having a child with someone.

"When I see my daughters friends with their dads, or think about my relationship with my own dad, I regret that she will never know that.

11

Financially, its been a struggle, too. Being the sole breadwinner is probably the toughest thing about parenting on your own, knowing that its all on you financially, Susie says.

Juggling work with school pick-up hours was hard. In fact, Ive gone self-employed, rented out my house and moved in with my mum to make things work not just when it comes to money, but also with things like attending school events.

"Ive been lucky to rely on my mum, which I know not everyone can. I didnt want to go through the process of being a solo mum only to miss out on school plays.

Being the sole breadwinner is probably the toughest thing about parenting on your own, knowing that its all on you financially.

As for how she became pregnant, Susie has been open with her daughter and anyone else who has asked from the start.

At first, I felt awkward telling people, but now I dont care. With Katie, I would talk to her even when she was too young to really understand, explaining that I had her by myself with a special seed from the doctor.

"Katie took it in her stride, and Ive even heard her say to people at school that she simply doesnt have a daddy.

11

According to Caroline, there are plenty of resources such as websites and books to help solo mums navigate telling their children, and most find their own way instinctively.

Another thing they have to consider, however, is the fact that their child may one day want to access their donors details.

We have whats called ID-release donation in this country, which means that at 18 a donor-conceived person can apply to the HFEA and ask: Am I donor conceived? If they are, they can ask for the donors name, date of birth and last known address, she explains.

The donor-conceived person can also learn of any siblings conceived using the same sperm. Susie says: If Katie wanted to find out who the donor was, I would fully support her when the time came.

11

SEW CLEVER Cleaning fan shows how to get old hair out off your vacuum roller for just 59p

ROOT ISSUE Mum splashes 35 on luxury M&S Christmas tree but gets dead twig instead

PRESENT AND CORRECT Parents swear by the 4-gift rule this Xmas which saves time & money

Exclusive

COUNTRY PAD Off-grid family will use benefits to build 'remote' home and will never work

HOL LOT OF STYLE Holly Willoughby stuns fans in fairytale princess gown for Dancing On Ice

SNOWHERE TO BE SEEN Can you spot the French bulldog among the polar bears in this puzzle?

Now Susie is hopeful the hardest part is over. Despite sometimes regretting that she was forced to make the choices she did, she wouldnt change her daughter for the world.

It does get easier as your child grows and you can communicate with them, she says. You become a little team.

"Those moments when its just me and her, snuggled in bed or on the sofa, make it all worth it. Sometimes I just look at Katie and think with awe: I made you!

*Names have been changed

GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAIL exclusive@the-sun.co.uk

Visit link:
Meet the women who are turning to sperm donation to become solo mums - The Sun

Postdoctoral Fellow in the Research Division for Molecular and Cell Biology job with THE UNIVERSITY OF HONG KONG | 188833 – Times Higher Education…

Work type: Full-timeDepartment: Research Division for Molecular and Cell Biology (25003)Categories: Academic-related Staff

Applications are invited for appointment as Post-doctoral Fellow in the Research Division for Molecular and Cell Biology (Ref.: 499200), to commence on March 1, 2020 for one year, with the possibility of renewal.

Applicants should possess a Ph.D. degree in genetics or developmental neurobiology, a strong background in using model organisms to study the genetic basis of neuronal differentiation and circuit formation, and a good publication record in relevant field. They should have excellent communication skills in written and spoken English, great trouble-shooting skills, effective collaboration skills and be able to conduct research independently. Those with research experience in the nematode C. elegans and skills in computational biology would have an advantage.

The appointee will carry out investigations in the field of developmental neurobiology using C. elegans as a model system and applying various genetics, genomics, and imaging techniques to study the mechanisms of neuronal differentiation and circuit assembly. He/She will participate in potential projects to study the mechanisms that regulate neurogenesis, cell fate decisions, and neuronal morphogenesis; and investigate the mechanisms that instruct the formation of electrical synapses in neural circuits. Background information about the research concerned can be found at http://www.zhenglabhku.org. Enquiries about the post should be sent to Dr. Zheng at cgzheng@hku.hk.

A highly competitive salary commensurate with qualifications and experience will be offered, in addition to annual leave and medical benefits. At current rates, salaries tax does not exceed 15% of gross income.

The University only accepts online application for the above post. Applicants should apply online and upload an up-to-date C.V., a brief statement of research interests, and the contact information of 2 referees. Review of applications will commence as soon as possible and continue until February 1, 2020, or until the post is filled, whichever is earlier.

Go here to read the rest:
Postdoctoral Fellow in the Research Division for Molecular and Cell Biology job with THE UNIVERSITY OF HONG KONG | 188833 - Times Higher Education...

Key Protein Linked to Aging Is Discovered – Technology Networks

Aging is a dramatic public health issue in the face of the current demographic changes: the proportion of 60 and over in the worlds population will almost double by 2050. In this context, a new discovery has just broadened scientific knowledge. Researchers from the Developmental and Stem Cell Biology Department at the Institut Pasteur shed light on the mechanisms of senescence, by identifying a key protein associated with aging.

Currently, most of older people die of noncommunicable diseases such as heart disease, cancer and diabetes, rather than infectious or parasitic diseases, even in developing countries. Thus, ageing is a major public health issue and the Institut Pasteur is committed to being a major player in research in this area.

A better understanding of the fundamental mechanisms that lead to ageing will pave the way towards ultimately healthier aging, which is a major socioeconomic issue for the coming decades.

Identification of a key protein linked to ageingSenescence, which is a process that limits proliferation of damaged cells in response to various types of stress, has been associated to aging. Accumulation of senescent cells in tissues may contribute to organ degeneration and age-related diseases. As a result, clearance of these cells has been associated with slower aging and longer healthspan in animal models.

Scientists from Institut Pasteur and CNRS demonstrated that progressive depletion of a protein drives proliferating cells into irreversible aging. Moreover, such a depletion is a very early trigger, and therefore a determinant of cellular aging, or senescence.

This factor, called CSB is involved in Cockayne syndrome, a disease affecting about one in every 200,000 people in European countries. The absence of CSB protein or its dysfunction causes early aging, photosensitivity, progressive neurological disorders and intellectual deficit in patients with Cockayne syndrome. We had previously shown that the absence or impairment of CSB is also responsible for dysfunction of mitochondria, the power plant of cells says Dr. Miria Ricchetti, head of the team Stability of Nuclear and Mitochondrial DNA within the Stem Cells and Development Unit at the Institut Pasteur. This new study reveals the very same alterations in replicative senescence, a process strictly linked to physiological aging says Ricchetti.

The importance of the present discovery is that it shows that a factor that was considered to be stable in normal cells is instead progressively depleted when they proliferate. When this happens, the cell is irreparably committed to the dead end of senescence.

The exhaustion of CSB is driven by epigenetic modifications (reversible and regulated modifications of gene expression, without altering the DNA) that block its expression at the DNA level. Moreover, a molecule previously identified by these researchers as being able to reverse the defects of Cockayne syndrome patient cells, is also able to attenuate the commitment of normal cells to senescence.

"These studies demonstrate an important link between the [pathological] accelerated aging process and normal aging, and also expose the CSB protein as a key factor against cellular aging" concludes Ricchetti.

Reference

Crochemore et al. (2019) CSB promoter downregulation via histone H3 hypoacetylation is an early determinant of replicative senescence. Nature Communications. DOI: https://doi.org/10.1038/s41467-019-13314-y

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Originally posted here:
Key Protein Linked to Aging Is Discovered - Technology Networks

Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies – BioSpace

Dec. 10, 2019 13:00 UTC

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive Discovery and Safety Services partnership with Bit Bio, a company that offers consistent and efficient reprogramming of human cells for use in research, drug discovery, and cell therapies.

By applying an engineering approach to synthetic and stem cell biology, Bit Bio has developed proprietary technologies for the efficient, consistent, and scalable reprogramming of induced pluripotent stem cells.

Cellular Reprogramming

Cellular reprogramming is the process by which human stem cells, given a precise set of genetic instructions, differentiate into a desired cell type. Current cellular reprogramming approaches are inefficient, with low cell yields, creating a gap for applications requiring high quality, consistent, and pure human cells.

To overcome this hurdle, Bit Bio has developed a gene engineering approach, opti-ox (optimised inducible over-expression). This platform, validated on both muscle and brain cells, enables precise, controllable stem cell reprogramming. According to Bit Bio, the process is more efficient and scalable than available technologies in transforming stem cells into desired cell types.

By combining the purity, scale, and speed of the opti-ox platform with deep learning algorithms, Bit Bio has the potential to accelerate the discovery and application of every single human cell type.

Partnering for Translational Drug Development

By partnering with Bit Bio, Charles River plans to offer clients access to an expanding suite of authentic human cells through their use in target discovery, validation and screening services. In drug discovery and safety, the use of high quality, authentic human cells at scale will enable the development of therapies with a higher chance of success in patients. Additionally, through the partnership, Charles River will contribute to the development and validation of novel cell lines.

Approved Quotes

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit http://www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005520/en/

See the article here:
Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies - BioSpace

Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting – Yahoo Finance

FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model

Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of Off-target Effects

Company Plans to Submit an IND Application for FT819 during 1H20

SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida.

FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D. The Company has now selected a single engineered iPSC clone, and generated and fully-characterized the master engineered iPSC bank for GMP production of FT819.

CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.

The Companys iPSC product platform unites stem cell biology and precision genetic engineering to create renewable master engineered iPSC lines that can be repeatedly used to mass produce cancer-fighting immune cells, replacing the high production costs, weeks of manufacturing time, and complex engineering processes required for current-generation CAR T-cell immunotherapies with an off-the-shelf product that has the potential to reach many more patients.

At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival. In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells. At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis.

As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Companys standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations. The Company selected the top-performing clone for generation of the master engineered iPSC bank for GMP production of FT819.

Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. In August, the Company announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,370,452 covering compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell, including an iPSC. The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.

Story continues

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Companys cell product candidates, including FT819, its ongoing and planned clinical studies, and the expected clinical development plans for FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company may cease or delay planned development and clinical trials of any of its product candidates for a variety of reasons (including any delay in enrolling patients in current and planned clinical trials, requirements that may be imposed by regulatory authorities on the conduct of clinical trials or to support regulatory approval, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, or the occurrence of any adverse events or other negative results that may be observed during development), the risk that results observed in preclinical studies of its product candidates, including FT819, may not be replicated in future clinical trials or studies, and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

View original post here:
Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting - Yahoo Finance

‘Adulting’ is hard. UC Berkeley has a class for that – Los Angeles Times

Conner Wright is carrying a demanding course load in his final year as an English major at UC Berkeley: antebellum American literature, introduction to music therapy and a research seminar on William Shakespeare.

The 20-year-old senior is immersed in the works of Henry David Thoreau, Ralph Waldo Emerson, Herman Melville and Harriet Jacobs.

But Wright, who is anticipating his graduation in May, has the self-awareness to know he needed a little something extra to prepare for his launch into a post-college world, that a superior ability to interpret classic literary works may not be enough.

So he signed up for a class on adulting, where he is learning to create and stick to a personal budget, build a resume and apply for jobs and navigate romantic relationships in a time when online interactions are eclipsing face-to-face encounters.

I need to learn how to get this adult thing down and manage life, Wright said.

The class, which has 30 students enrolled in each section, is led by two Berkeley undergrads who plan discussion topics and schedule guest speakers to fill 90 minutes each week. The adults in training are among thousands of people across the country who have signed up for courses that focus on things such as cooking or budgeting or time management.

Jenny Zhou, left, and Belle Lau teach an adulting class at UC Berkeley.

(Josh Edelson / For The Times)

Adulting classes for college students and postgrads have swelled in popularity in recent years, in part because many high schools have largely abandoned life skills courses such as home economics, which were created to help students navigate the path to adulthood.

That trend, combined with armies of hovering parents who emphasize academic achievement to the exclusion of almost everything else, has resulted in university classrooms filled with students who scored a 5 on their AP Physics test, but struggle to plan for a weeks worth of groceries and meals.

In Portland, Maine, the Adulting School offers in-person classes on soft skills, such as interviewing, conflict resolution and making friends, along with topics such as personal finance and basic home maintenance.

Principal Rachel Flehinger said her students, who are typically in their 20s and 30s, have experienced their share of disdain over their so-called entitlement and laziness.

Weve had clients who are millennials having major anxiety that they didnt have these skills and didnt feel successful as an adult, she said. Theres a lot of self-loathing that happens.

Similar classes or in-person workshops have popped up at libraries and universities across the country, in private groups on social media and even on blogs tailored to college students. Some high schools have scheduled seminars on life skills as a way to prepare their students for life after graduation.

Sometimes students come up with their own solutions.

Neither Belle Lau of Washington nor Jenny Zhou of Arizona felt fully prepared for life away from home when they arrived at Berkeley two years ago. When Lau moved out of the dorms and into her own apartment during her sophomore year, her lack of self-reliance at the time became apparent. She was working, attending classes and, for the first time, had to plan her own meals, put money aside and cover her expenses. She quickly realized that she was spending too much money eating out all the time.

More than 200 students at UC Berkeley applied for two adulting courses offered this semester. More than half of them had to be turned away because of limited class size.

(Josh Edelson / For The Times)

Lau and Zhou noticed that many of their peers were having similar struggles.

Were thrown out into this world and have little idea about what the heck were supposed to do, said Lau, 21. I think in general we all feel a little bit lost and dont know where to start.

To remedy that, Lau and Zhou, 20, decided to create their own class.

When it was first offered last spring, every one of the 30 spots was filled. Seventy students had to be turned away.

Lau and Zhou added a second session this semester. More than 200 students filled out applications explaining why they wanted to take the 12-week course. The women accepted fewer than half who applied.

Column One

A showcase for compelling storytelling from the Los Angeles Times.

Adulting is one of dozens of student-run courses in the universitys DeCal (Democratic Education at Cal) program, in which students create and facilitate their own classes on topics that include those practical and fun and often arent addressed in traditional curriculum. The project is rooted in the ideals of Berkeleys free speech movement, launched in the 1960s when students pressed for and won greater academic rights.

Theres a class on criminal psychology, which aims to analyze the minds of criminals, particularly of those who commit heinous crimes, in an effort to understand factors that influenced their behaviors and led them to commit violent offenses. Students enrolled in Intro to Baking learn to make bread, cakes, pastries and other confections without setting you or your roommates on fire, according to the course catalog.

Another course takes participants on a journey to Hogwarts School of Witchcraft and Wizardry through discussions of Harry Potter novels.

The courses in DeCal count for one or two credits and are offered as pass/no pass; as a result, students say they are unlikely to add to their stress levels.

College is a time of so many transitions the losing of certain reference points and its relatively sudden, said Nancy Liu, an assistant clinical professor of psychology at UC Berkeley and the faculty sponsor for the adulting class this semester. Youre on your own for the first time, youre navigating a large system with limited support, youre taken out of past comforts and starting anew, you have new tasks that youve never had to deal with before.

Add to that the stress of a high-pressure academic environment, it makes sense that many would feel overwhelmed, she said.

College also sets the tone for much of what comes afterward: fostering those daily habits and routines; balancing work, school and life; remembering to file your taxes and keeping a budget; learning how to navigate interpersonal challenges with less scaffolding or support from experienced others. It seems crucial to address it head-on in a way that was valuable to students, Liu said.

Students learn basic life skills that experts say have been abandoned by traditional academia.

(Josh Edelson / For The Times)

When Lau and Zhou decided to create a class, they initially envisioned a course in cooking, a passion they share. That idea morphed into life hacks and, later, adulting.

When the two began brainstorming a syllabus, daily tasks such as laundry, sewing and car maintenance didnt make the cut. Instead, they focused on topics that are more abstract: time management, budgeting, fitness and nutrition, and relationships.

Each 90-minute session features a presentation from Zhou and Lau, juniors majoring in molecular and cell biology and integrative biology, respectively, and an outside expert who visits the class in person or via video chat. Last year, a recruiter from Lyft prepped students about job searches and a former accountant discussed filing taxes.

Those accepted into the classes, mostly seniors, have lamented that many of the things they were learning werent taught by their parents.

Laus mother, Allie Wu, says that parents dont trust their kids enough to do things on their own, adding that when theyre at home their parents pretty much take care of everything for them.

Wu says she has always been very independent, a trait that was a necessity when she arrived in the United States from Taiwan as a 22-year-old to pursue her MBA. Wu hoped her daughter would leave home with the same sense of self-sufficiency. But when Lau confessed to her mother that she struggled a bit her first year at Berkeley, Wu said she began to worry.

Those concerns dissipated when Lau told her about the adulting class she wanted to start with a friend.

Wu, who visited the class last year to talk about taxes, said the course is wonderful and unique.

I know shes in a good place now. Im very proud of her, Wu said. She knows what she wants and what she needs to accomplish her goals.

UC Berkeley students Belle Lau, left, and Jenny Zhou teach an adulting class for their peers.

(Josh Edelson / For The Times)

During the first week of adulting at Berkeley this semester, students were asked to come up with goals that were SMART specific, measurable, attainable, relevant and time-based.

To kick it off, Zhou asked whether anyone had ever set a goal they didnt accomplish.

A few hands shot up. Several people shifted uncomfortably in their chairs. A handful looked around the room.

In less than a minute, everyones hand was in the air.

After a brief lecture, Lau and Zhou split the class into groups of six, each assigned to discuss their goals for the semester. Precision was rewarded; vagueness had to be remedied.

Students shuffled their desks into haphazard circles in the classroom and made quick introductions. They bantered about the dread of 8 a.m. classes and late-night studying marathons that would compound that trepidation as the semester dragged on.

Then things got uncomfortable.

Some of the students spoke in hushed tones as they shared the goals they had written on sheets of paper in front of them and, along with those, their insecurities that they might not be doing this whole grown-up thing quite right.

Wright spoke up first. His goal was to build more healthful habits with diet and exercise before graduation. The group nodded in agreement.

Several students said better time management would make a huge difference in their lives. One woman, a junior, said planning and establishing a routine might keep her from staying up all night cramming for exams.

Another piped up, saying shed like to get more done during the day by limiting how much time she spends on her phone a common distraction.

Kate Curtis, a 21-year-old senior who showed up 10 minutes late to the class with a look of embarrassment and a quick apology, said shes long struggled with punctuality. Shes been late so many times to her job at a fast-food restaurant that her manager recently pulled her into a meeting to discuss it. She was humiliated and ashamed.

I want to learn to be dependable. I want other people to be able to count on me, she said.

Curtis, who transferred to Berkeley from a community college in Orange County, said she lived at home for the first two years of college and feels she was coddled longer than her peers.

Im eight hours away from home now, so Im actually on my own. I have to find my own doctor if Im sick. Ive just signed up for my first loan, and Im not really understanding what Im getting into, she said.

Lau acknowledged that she and Zhou dont have all the answers, but shes quick to note that parents shouldnt be faulted for their childrens lack of real-world knowledge.

Maybe it is our parents who arent teaching us these things we thought we should already know, but we dont want to blame our parents for us being naive or ignorant, she said. Its our responsibility as college students to know that if were struggling in some aspect, there are resources out there for us.

Read the rest here:
'Adulting' is hard. UC Berkeley has a class for that - Los Angeles Times

GE Healthcare Life Sciences pairs up with Advanced Solutions Life Sciences to create new opportunities for regenerative tissue manufacturing -…

MARLBOROUGH, Mass. & LOUISVILLE, Ky.--(BUSINESS WIRE)--GE Healthcare Life Sciences and Advanced Solutions Life Sciences (ASLS) will enter into a strategic R&D and distribution partnership that sets out to personalize tissue regeneration. The integration of IN Cell Analyzer and BioAssemblyBot systems technologies will embed cellular-level assessments into the 3D-bioprinting workflow used to create human tissue models.

Bioprinted tissues are small in size and die quickly, due to an inability to engineer small blood vessels the bodys supply network. ASLS patented Angiomics technology enables bioprinted microvessels to self-assemble into functional capillary beds, which deliver nutrients, oxygen, and hormones to the 3D tissue model and remove waste. This partnership would allow life scientists and tissue engineers to quickly design, build and image living, vascularized 3D tissues in a single, agile process.

Emmanuel Abate, General Manager of Genomics & Cellular Research, GE Healthcare Life Sciences, says: Printing multi-material 3D objects inside of microwell plates allows scientists to efficiently move away from traditional 2D monocultures on plastic, to 3D discovery and cytotoxicity models that more accurately reflect native biology and disease. By combining this flexibility and precision of the BioAssemblyBot with the image quality and speed of the IN Cell Analyzer 6500 HS confocal screening platform, the prospect of automating high content screening in 3D models can become a reality.

Currently, biopharmaceutical companies test their drugs in 2D models and animal models. Precise 3D models provide a more physiologically relevant environment for drug testing because they mimic human reactions.

The power of both of these platforms brings a new level of efficiency, speed and quality with assay designs and 3D biofabrication, says Michael Golway, President & CEO of ASLS.

Traditional 3D bioprinters are not designed for quality or interoperability with the high-throughput screening methods that pharmaceutical developers use to identify drug candidates. This alliance will result in a new product to address this challenge: an integration of GE Healthcare Life Sciences IN Cell Analyzer confocal imaging platform with IN Carta cell analysis software, and ASLS BioAssemblyBot 3D bioprinter with TSIM design software.

For pharmaceutical companies, where the average time to develop a new drug candidate may take over seven years, moving from traditional stage-gate testing processes to a lean, agile workcell for 3D tissue fabrication and assessments will shorten development timelines. The integration between IN Cell Analyzer and BioAssemblyBot enables the automated inclusion of cellular imaging information into the tissue modeling process so that new therapies can be scaled more quickly and effectively.

To learn more, please go to http://www.lifesciences.solutions/GE

For a live demonstration visit booth #908 at the joint meeting of the American Society of American Cell Biology (ASCB) and the European Molecular Biology Organization in Washington, DC taking place from December 7-11, 2019.

About GE Healthcare Life Sciences:

GE Healthcare Life Sciences helps therapy innovators, researchers and healthcare providers accelerate how precision diagnostics and therapies are invented, made and used. Our products enable biological analysis, research, development and the manufacture of advanced therapies and vaccines. Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Visit our website https://www.gelifesciences.com/about-us for more information.

About Advanced Solutions Life Sciences:

Advanced Solutions Life Sciences (ASLS) is dedicated to the discovery, design, and development of integrated software and hardware solutions for the fields of science that involve living organisms, molecular biology, and biotechnology. ASLS offers a full-service business model including its patented, cGMP and UL certified BioAssemblyBot platform, as well as BioBot Basic, TSIM and BioApps Software, VIPM, and Professional Services. Visit http://www.bioassemblybot.com for more information.

See the original post here:
GE Healthcare Life Sciences pairs up with Advanced Solutions Life Sciences to create new opportunities for regenerative tissue manufacturing -...

Malaria-Transmitting Parasites Seem To Be Hampered By Minestrone And Other Soups : Goats and Soda – NPR

It could be that malaria-carrying parasites are rendered less potent by minestrone. hmproudlove/Getty Images hide caption

It could be that malaria-carrying parasites are rendered less potent by minestrone.

Bring in some soup.

The unusual homework assignment at London's Eden Primary School was for a science week project cooked up by parent Jake Baum. He's a professor of cell biology and infectious diseases at Imperial College London, and his lab's job is to find new ways to combat malaria, which kills half a million children each year.

Baum figured he could teach young students about the process of medical research through something both tasty and understandable: the go-to soup recipes their families use when someone gets sick.

"What makes a good medicine versus hocus-pocus?" explains Baum, who regularly preps his own favorite home remedy, something he calls "Jewish grandmother's chicken soup."

"It was not the plan to discover anything," he adds.

Sixty students transported their soup submissions to school in 15 milliliter plastic tubes. That's about 1 tablespoon. The soup was frozen, thawed (standard practice for samples) and then (much to the children's delight) centrifuged spun in a machine to separate different substances.

At the next step, filtration, four samples were determined to be too dense or oily to test. Although they were likely delicious, they didn't make it to the lab stage, where the remaining 56 samples were tested in two ways against the P. falciparum parasite the species responsible for 99% of malaria deaths.

First, researchers checked what effect the soups had on asexual growth during the disease-causing stage. Or, to put it in primary school terms, they were looking through the microscope for the color green.

"More green means [the parasites are] happy. With an inhibitor like a drug, it's less green," Baum says. They followed up by checking on male parasite sexual development, which is responsible for disease transmission. For that, they recorded the movement of the parasites because, as Baum notes, "sperm wiggle."

To Baum's surprise, with five of the soups, the color green was much dimmer five of them were able to suppress growth by over 50% (and two of these even did about as well as a leading antimalarial, dihydroartemisinin).

In other soups, there was a lot less wiggling. Four were found to have blocked transmission activity by more than 50%.

"We just said, 'Wow, what do we do with this?' " Baum says.

The answer turned out to be another teachable moment for the students, ages 4 to 11, who participated in the study. Although the results were collected within a few months, it took two years for the work to get published. Another Eden Primary parent, pediatric nephrologist Stephen Marks, helped pitch the study to journals and championed the idea that the children of the school should be listed as authors which they were when the study was finally released in November in the Archives of Disease in Childhood.

"Every kid can say they've had their first scientific paper," says Baum, who jokes that some may want to turn it into a paper airplane.

But it was a project they're likely to remember, notes Susanna Daniels, another parent/scientist, who also happens to be a soup enthusiast. As soon as her two children in the school came home to tell her about the experiment, there was some hypothesizing going on. "Our oldest was most disappointed because I'm a pescatarian. She was anxious our soup would fail because it wasn't chicken soup," explains Daniels, who opted to make her mother's veggie minestrone, loaded with cabbage, carrots, celery and tomato.

Turns out, that combo did especially well in the study, accounting for two of the samples that helped block transmission activity. "It wasn't a fluke finding because it was duplicated in both samples," Daniels says. The kids were thrilled to get the news, she adds. "They wanted to ring my mum straight away. She was quite bemused by the whole thing."

It's not so far-fetched to search for medical breakthroughs in your grandma's or great uncle's kitchen concoctions, Baum says, pointing to the scientific literature extolling the curative properties of chicken soup. (Research studies like this one suggest that it curbs some symptoms of upper respiratory tract infections.)

In terms of malaria treatment, the original lifesaving medicine was quinine, found in the bark of the South American cinchona tree. Today, the most commonly recommended anti-malaria drugs are derived from the artemesia plant (aka wormwood), which has been prescribed in traditional Chinese medicine for over 1,000 years. As Baum says, "Nature can produce fantastic molecules."

Pinpointing what exactly it was about these specific soups that had an effect would take years of additional research. For starters, it's hard to even tell what was in them. A bright red one probably contained beets, and a lot of them smelled like chicken. But students were never asked for a list of ingredients. Even though some kids had written information on the plastic tube samples they submitted, "when we wiped the tubes with ethanol, we lost the recipes," Baum says.

No one is claiming that these soups offer a promising pathway to a cure. "I'm using a lot of 'could, would, possibly,' " notes Baum, who doesn't have current plans for more soup experiments. But if he did and the resources were available he'd love to see it performed globally. Although the Eden Primary students come from diverse ethnic backgrounds, Baum says, they're all doing their grocery shopping in London. They can't pluck a leaf from a particular kind of bush the way kids in other parts of the world might.

Building on local knowledge is vital in malaria research, agrees Stephanie Yanow, a global health professor at the University of Alberta, who was not involved in the soup study. "We're at a difficult point every intervention we've tried, the parasite is always ahead of the game. Malaria numbers are going up in some places. There's drug resistance. The vaccine we have isn't very effective," she says. "We need to think outside the box and use more unconventional methods."

What struck her about the project was how well it engaged kids and their families and encourages "citizen scientists," or people without formal scientific training, to get involved in research.

And it's definitely made Yanow wonder what mysteries await in her minestrone. "There's a reason we think of it as a comfort food," she says.

Vicky Hallett is a freelance writer who regularly contributes to NPR.

Read the original:
Malaria-Transmitting Parasites Seem To Be Hampered By Minestrone And Other Soups : Goats and Soda - NPR

Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug…

DetailsCategory: AntibodiesPublished on Monday, 09 December 2019 18:35Hits: 253

CAMBRIDGE, MA, USA I December 09, 2019 IMagenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its CD117-ADC patient preparation program were presented at the 61st Annual Meeting of the American Society of Hematology (ASH). These results, which were highlighted in an oral presentation at ASH by John Tisdale, M.D., Director, Molecular and Clinical Hematology Section, National Institutes of Health, showed the first-ever successful transplant of gene-modified cells in non-human primates using a targeted, single-agent antibody-drug conjugate (ADC), without the use of chemotherapy or radiation.

Todays conditioning regimens involve high doses of chemotherapy, often paired with radiation, to remove the disease-causing cells. As a result, patients undergoing gene therapy or stem cell transplant are all faced with a difficult choice: whether to endure severe toxicity and risk infertility and cancer for the chance for a cure. Magentas portfolio of targeted ADCs represents an extremely promising new option to prepare patients for gene therapy or transplant with no need for toxic chemotherapy or radiation, said Dr. Tisdale. The results presented today show that a single dose of single agent CD117-ADC achieves the same level of depletion as four doses of busulfan chemotherapy to enable successful engraftment and persistence of stem cells modified with the -globin gene, the gene that causes sickle cell disease and -thalassemia when mutated. Importantly, the animals undergoing preparation with CD117-ADC showed none of the damaging toxicities associated with busulfan conditioning.

Magenta is the only company with the people, platforms and a product engine committed to comprehensively transforming immune and blood system reset, which includes revolutionizing the toxic methods that are used to prepare patients for gene therapy and transplant today. said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. The gene therapy field has learned that higher levels of stem cell depletion, which meant higher doses of busulfan, were needed to ensure long-term engraftment of the gene-modified cells and persistence of gene therapy. Across all the modalities we have tested, we have seen that ADCs are most effective at achieving these high levels of stem cell depletion without chemotherapy to enable engraftment and long-term durability of the transplant. Todays impressive results provide important validation of the ADC approach as well as the CD117 target for patient preparation and underscore Magentas leadership in the field of conditioning.

Results from the CD117-ADC Patient Preparation Program

Title: A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates (Abstract #610) Presenter: John Tisdale, M.D., Director, Molecular and Clinical Hematology Section, National Institutes of Health, Bethesda, Md.

Magentas most advanced patient preparation program, CD117-ADC, targets CD117, a protein expressed on hematopoietic stem cells. CD117-ADC is designed to remove the genetically mutated cells in the bone marrow that cause certain genetic diseases, such as sickle cell disease, enabling curative stem cell transplant or gene therapy.

Results presented by Dr. Tisdale showed:

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

SOURCE: Magenta Therapeutics

More:
Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug...

ERC promotes CRISPR research to better treat infections – News-Medical.net

Chase Beisel heads the "Synthetic Biology of RNA" research group at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Wrzburg, a branch of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and run in collaboration with the Julius-Maximilians-Universitt in Wrzburg. With the Consolidator Grants, the European Research Council (ERC) promotes research by up-and-coming scientists in Europe.

CRISPR is a word on everyone's lips at the moment. Although it sounds somewhat crispy and delicious, it is in fact inedible - it is actually one of the most promising tools of genetic engineering. CRISPR stands for "Clustered Regularly Interspaced Short Palindromic Repeats". These short DNA segments in the genome of bacteria are named after their regular pattern of repeating and mirrored sequences. They act as effective virus defence systems for bacteria. Copies of the CRISPR DNA exist in the form of RNA fragments in the cell. In the event of a viral attack, where a virus injects its DNA into a bacterium, the defence mechanism is triggered: The proteins, which include Cas9, is called to action and compares the sequence of the foreign DNA with that of the CRISPR RNA fragments. If it finds a matching counterpart, Cas9 cuts the foreign virus DNA, thus rendering the intruder harmless. The CRISPR-Cas9 system is therefore also known as genetic scissors and is now used for genome editing. DNA sequences can be specifically cut and modified in the laboratory using custom-designed CRISPR gene scissors, for example for the development of improved crops or medicines, for the manufacture of industrially used microorganisms, and in human cells for treating genetic diseases.

American chemical engineer Chase Beisel dedicated himself to CRISPR research around nine years ago. "We have an incredibly powerful genetic engineering tool at our disposal," says Beisel. "In order to fully and safely utilise its potential in the future, it is important that we better understand the basic biological relationships of CRISPR complexes in bacteria." The bacterial immune system can evidently learn new things and arm itself against other attackers by quickly integrating parts of foreign DNA into its own genome. CRISPR arrays encode the memory of previous infections and enable multiple intruders to be attacked simultaneously. How exactly these advanced CRISPR complexes are created, which criteria are used for selecting new sequences and which key genes of the attacker are thus rendered ineffective are not yet fully understood. This is exactly where Beisel's current research project "CRISPR Combo" aims to start, addressing the unanswered questions. "In addition to researching the biological fundamentals of CRISPR arrays in bacteria, we would also go one step further in the direction of a genetic application of CRISPR arrays," says Beisel. "To do this, we will use designed CRISPR arrays to target multiple genes at once in pathogens, thereby identifying combinations that most drive infections and providing new drug targets."

In 2018, Beisel moved from the Department of Chemical and Biomolecular Engineering at the North Carolina State University in Raleigh (USA) to the HIRI in Wrzburg, where he has been the head of the "RNA Synthetic Biology" research group for two years now. His twelve-person team consists of postdocs, doctoral candidates, technicians and students. "The funding from the ERC means I can confidently add four members to the team - that is really fantastic," says Beisel. "The ERC Grant is an important milestone for me personally. Making the leap to Germany to join the HIRI was absolutely the right decision, and I am delighted about this funding. It enables me to dedicate my research to a topic that fascinates me and at the same time offers significant benefits for society as a whole."

Posted in: Medical Science News | Medical Research News | Disease/Infection News

Tags: Bacteria, Cas9, Cell, CRISPR, DNA, Gene, Genes, Genetic, Genetic Engineering, Genome, Genome Editing, Hospital, Immune System, Laboratory, Palindromic Repeats, Research, Research Project, RNA, Virus

Continued here:
ERC promotes CRISPR research to better treat infections - News-Medical.net